GENE ONLINE|News &
Opinion
Blog

2021-09-02| COVID-19

Why Are Human DNA Vaccines Such a Big Deal?

by Ameya Paleja
Share To
The Central Drugs Standard Control Organisation (CDSCO), the national regulator of pharmaceutical products in India created history on August 20th, by approving a DNA-based vaccine against COVID-19. This is the first instance when a DNA-based vaccine has been approved for use in humans ever. Previously, DNA-based vaccines were first tried out in the 1990s and were approved for veterinary use. So, what was stopping them from being used in humans?

How Does a DNA Vaccine Work?
Conventional vaccines use live attenuated organisms or a part of them as an antigen to induce an antibody response. DNA-based vaccines carry this information in plasmids and rely on host cell machinery to express them. To do this, the plasmid first needs to enter the host cell nucleus. Depending on the host, a specific promoter sequence is used to ensure the plasmid DNA transcription. The cellular protein-making mechanism then follows up to make up the antigen and express it. 

GO Prime with only $1.49 now

LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top